JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 2023
CAS [942487-16-3]
MF C23H25F3N6O2MW 474.48
Potent, orally bioavailable, ATP-competitive and reversible inhibitor of aurora kinase A (IC50: 0.8 nM) and aurora kinase B (IC50: 5 nM) with potential antineoplastic activity; PF 03814735 also inhibits Flt1, FAK and TrkA with IC50 values of 10, 22, 30 nM respectively; clinical candidate.
KEYWORDS: PF 03814735 | supplier | Aurora inhibitor | PF03814735 | PF-03814735 | CAS [942487-16-3] | Histone | Survivin | Topo | TPX2 | Aurora kinase | antineoplastic activity | Flt1 | FAK | TrkA | clinical candidate
N-[2-[(1S,4R)-6-[[4-(cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,2,3,4-tetrahydronaphthalen-1,4-imin-9-yl]-2-oxoethyl]-acetamide
[942487-16-3]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
* Required Fields